Kamada Ltd. (NASDAQ and TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces financial results for the three and nine months ended September 30, 2013.
“Overall we are very pleased with our third quarter financial performance. We made continued steady progress growing proprietary product revenue, advancing clinical development programs and enhancing manufacturing processes to meet expected product demand,” stated David Tsur, Founder and Chief Executive Officer of Kamada.
Help employers find you! Check out all the jobs and post your resume.
